Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Melanie E. Royce"'
Autor:
Melanie E. Royce, Diaa Osman
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 2015, Iss 9, Pp 73-79 (2015)
Externí odkaz:
https://doaj.org/article/a6bc0af339b0477a9f1e1a651b533c22
Autor:
Gwynn Ison, Rajeshwari Sridhara, Melanie E Royce, Tatiana M. Prowell, Shenghui Tang, Erik Bloomquist, Joyce Cheng, Laleh Amiri-Kordestani, Christy Osgood, Suparna Wedam, Jennifer J. Gao, Danielle Krol, Richard Pazdur, Julia A. Beaver
Publikováno v:
SSRN Electronic Journal.
Background: Cyclin dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as 1st or 2nd line treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 (HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::27eb5a2056c752b3ad3405033cd42eec
https://doi.org/10.2139/ssrn.3864896
https://doi.org/10.2139/ssrn.3864896
Autor:
Suparna Wedam, Shenghui Tang, Laleh Amiri-Kordestani, Richard Pazdur, Rajeshwari Sridhara, Tatiana M. Prowell, Melanie E Royce, Jennifer J Gao, Julia A. Beaver, Christy Osgood, Joyce Cheng, Danielle Krol, Gwynn Ison, Erik Bloomquist
Publikováno v:
Journal of Clinical Oncology. 39:1055-1055
1055 JJG, JC, TMP contributed equally. JAB, LAK contributed equally. Background: Cyclin dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as first or secondline treatment of hormon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a426ad584d2fcbf3dc967ad911bbd900
https://doi.org/10.1200/jco.2021.39.15_suppl.1055
https://doi.org/10.1200/jco.2021.39.15_suppl.1055
Publikováno v:
Journal of Clinical Oncology. 39:e18787-e18787
e18787 Background: Aligning with 21st Century Cures legislation, the FDA is exploring trial design modernization and methodology to advance appropriate uses of Real World Data (RWD) to generate Real World Evidence (RWE). The Oncology Center of Excell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb99a51c8c629b3347931e0bb7763f50
https://doi.org/10.1200/jco.2021.39.15_suppl.e18787
https://doi.org/10.1200/jco.2021.39.15_suppl.e18787
Autor:
Roisin M Connolly, Fengmin Zhao, Kathy D Miller, Min-Jung Lee, Richard L Piekarz, Karen L Smith, Ursa Brown-Glaberman, Jennifer S Winn, Bryan A Faller, Adedayo A Onitilo, Mark E Burkard, George T Budd, Ellis G Levine, Melanie E Royce, Peter A Kaufman, Alexandra Thomas, Jane B Trepel, Antonio C Wolff, Joseph A Sparano
Publikováno v:
Cancer Research. 81:GS4-02
Background: Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with use of histone deacetylase (HDAC) inhibitors such as entinostat. The ENCORE 301 randomized phase II study reported an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0af8bccf428efb7d1b917fc42918e9fd
https://doi.org/10.1158/1538-7445.sabcs20-gs4-02
https://doi.org/10.1158/1538-7445.sabcs20-gs4-02
Autor:
Melanie E Royce
Publikováno v:
Breast Cancer Management. 5:89-92
Melanie E Royce* speaks to Roshaine Wijayatunga, Managing Commissioning Editor: Melanie E Royce is a Professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of New Mexico Comprehensive Cancer Center (UNM CC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab7913aec10ce7621d268010323347c2
https://doi.org/10.2217/bmt-2017-0001
https://doi.org/10.2217/bmt-2017-0001
Autor:
Reina Armamento-Villareal, Vallabh O Shah, Lina E Aguirre, Angela W Meisner, Clifford Qalls, Melanie E Royce
Publikováno v:
Frontiers in Genetics, Vol 7 (2016)
Given the racial/ethnic disparities in breast cancer, we evaluated the association between CYP19A1 single nucleotide polymorphisms (SNPs) on disease progression in women with breast cancer from different racial/ethnic backgrounds. This is a cross-sec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcfa41c4d2eec71b951bcd5306f190c6
https://doi.org/10.3389/fgene.2016.00211
https://doi.org/10.3389/fgene.2016.00211
Autor:
Ronald S. Walters, Rosni Adinin, James L. Wade, Lajos Pusztai, Vicente Valero, Karen Hoelzer, Banu Arun, Gabriel N. Hortobagyi, Edgardo Rivera, Melanie E. Royce
Publikováno v:
Journal of Clinical Oncology. 21:3249-3254
Purpose: We conducted a phase II clinical trial to determine the clinical efficacy and safety of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Patients and Methods: Patients were eligible i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58183c9d3b148ac18de44a57a59b992d
https://doi.org/10.1200/jco.2003.03.111
https://doi.org/10.1200/jco.2003.03.111
Publikováno v:
American Journal of Clinical Oncology. 24:421-424
We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350414aeea8471acb07a3c1bf5b014a5
https://doi.org/10.1097/00000421-200108000-00026
https://doi.org/10.1097/00000421-200108000-00026
Publikováno v:
Drugs & Aging. 17:201-216
Fluorouracil has been the mainstay of treatment for colorectal cancer (CRC) for almost 40 years. Various schedules and biochemical modulators have been investigated in an attempt to improve the therapeutic efficacy of fluorouracil. To date, fluoroura
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dce8f3efc52a72ae08c73e5c101327d5
https://doi.org/10.2165/00002512-200017030-00004
https://doi.org/10.2165/00002512-200017030-00004